↓ Skip to main content

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Overview of attention for article published in Journal of Hematology & Oncology, October 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

patent
3 patents

Citations

dimensions_citation
343 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Published in
Journal of Hematology & Oncology, October 2016
DOI 10.1186/s13045-016-0332-8
Pubmed ID
Authors

Yongkun Sun, Wei Niu, Feng Du, Chunxia Du, Shuting Li, Jinwan Wang, Li Li, Fengqing Wang, Yu Hao, Chuan Li, Yihebali Chi

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 72 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 15%
Student > Ph. D. Student 8 11%
Student > Bachelor 8 11%
Student > Doctoral Student 7 10%
Student > Postgraduate 7 10%
Other 11 15%
Unknown 20 28%
Readers by discipline Count As %
Medicine and Dentistry 21 29%
Biochemistry, Genetics and Molecular Biology 9 13%
Chemistry 3 4%
Nursing and Health Professions 2 3%
Agricultural and Biological Sciences 2 3%
Other 11 15%
Unknown 24 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2022.
All research outputs
#3,649,942
of 23,445,423 outputs
Outputs from Journal of Hematology & Oncology
#275
of 1,213 outputs
Outputs of similar age
#59,370
of 321,618 outputs
Outputs of similar age from Journal of Hematology & Oncology
#5
of 27 outputs
Altmetric has tracked 23,445,423 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,213 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,618 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.